Craig N. Sawchuk, PhD
Department of Psychiatry and Psychology
CNS declares that he has no competing interests.
Jason P. Veitengruber, MD
Department of Psychiatry and Behavioral Sciences
University of Washington School of Medicine
JPV declares that he has no competing interests.
Bunmi O. Olatunji, PhD
Department of Psychological Sciences
BOO declares that he has no competing interests.
Stacy Shaw Welch, PhD
Anxiety and Stress Reduction Center of Seattle
University of Washington
SSW declares that she has no competing interests.
Richard P. Swinson, MD, FRCPC, FRCPsych
Anxiety Treatment and Research Centre
McMaster University and St Joseph’s Hospital
RPS declares that he has no competing interests.
Jeffrey M. Lohr, PhD
Department of Psychology
University of Arkansas
JML declares that he has no competing interests.
David F. Tolin, PhD
Institute of Living
DFT declares that he has no competing interests.
David Baldwin, MD
Professor of Psychiatry
University of Southampton
DB has acted as a consultant for and held research grants from Cephalon, Eli Lilly, GSK, Lundbeck, Organon, Pfizer, Pharmacia, Roche, and Wyeth and has also acted as a consultant to Asahi, AstraZeneca, Grunenthal, Pierre Fabre, Servier, Sumitomo, and Wyeth. He has accepted paid speaking engagements in industry-supported satellite symposia and is co-author of the BAP evidence-based guidelines on the treatment of anxiety disorders. He is also a Medical Patron of Anxiety UK.